Cargando…

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene

Significant improvements in the survival rates of paediatric cancer have been achieved over the past decade owing to recent advances in therapeutic and diagnostic strategies. However, disease progression and relapse remain a major challenge for the clinical management of paediatric angiosarcoma. Com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cervi, Catherine, Sápi, Zoltán, Bedics, Gábor, Zajta, Erik, Hegyi, Lajos, Pápay, Judit, Dezső, Katalin, Varga, Edit, Mudra, Katalin, Bödör, Csaba, Csóka, Monika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997097/ https://www.ncbi.nlm.nih.gov/pubmed/36910630 http://dx.doi.org/10.3389/fonc.2023.999810

Ejemplares similares

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Novel RICTOR amplification harbouring entities: FISH validation of RICTOR amplification in tumour tissue after next-generation sequencing
por: Sztankovics, Dániel, et al.
Publicado: (2023)

Germline MUTYH mutations and high‐grade gliomas: Novel evidence for a potential association
por: Bedics, Gábor, et al.
Publicado: (2022)

Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification
por: Hempel, Dirk, et al.
Publicado: (2020)

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
por: O’Reilly, E M, et al.
Publicado: (2019)

Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
por: Deland, Lily, et al.
Publicado: (2021)

Nodular fasciitis: a comprehensive, time-correlated investigation of 17 cases
por: Sápi, Zoltán, et al.
Publicado: (2021)

Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
por: König, David, et al.
Publicado: (2022)

Novel actionable ROS1::GIT2 fusion in non-Langerhans cell histiocytosis with central nervous system involvement
por: Bedics, Gábor, et al.
Publicado: (2022)

Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report
por: Tadipatri, Ramya, et al.
Publicado: (2022)

Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors
por: Rosen, Ezra Y., et al.
Publicado: (2019)

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
por: Waguespack, Steven G, et al.
Publicado: (2022)

Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib
por: Sahni, Shubham, et al.
Publicado: (2023)

Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib
por: Alharbi, Musa, et al.
Publicado: (2020)

Larotrectinib in a NTRK‐rearranged soft tissue sarcoma in the neoadjuvant setting: A case report
por: Percy, Catherine, et al.
Publicado: (2021)

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer
por: Frehner, Lorenz, et al.
Publicado: (2023)

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion
por: Bielack, S S, et al.
Publicado: (2019)

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
por: DuBois, Steven G., et al.
Publicado: (2018)

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence
por: Ricciuti, Biagio, et al.
Publicado: (2019)

Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion
por: Wu, Lawrence W., et al.
Publicado: (2018)

Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
por: Hemming, Matthew L., et al.
Publicado: (2020)

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
por: Yang, James C. H., et al.
Publicado: (2022)

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
por: Doz, François, et al.
Publicado: (2021)

Antitumor Activity of Larotrectinib in Tumors Harboring NTRK Gene Fusions: A Short Review on the Current Evidence [Corrigendum]
Publicado: (2020)

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report
por: Palmerini, Emanuela, et al.
Publicado: (2023)

Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
por: Garcia-Foncillas, Jesus, et al.
Publicado: (2022)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma
por: Ziegler, David S., et al.
Publicado: (2018)

Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy
por: Kasi, Pashtoon M, et al.
Publicado: (2022)

Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment
por: Chen, Weijie, et al.
Publicado: (2021)

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
por: Pitoia, Fabián
Publicado: (2021)

Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers
por: Michels, Renée E., et al.
Publicado: (2022)

NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma
por: Wang, Yuekun, et al.
Publicado: (2020)

Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
por: Strohmeier, Simon, et al.
Publicado: (2021)

TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by NTRK Fusions
por: Cappellesso, Rocco, et al.
Publicado: (2022)

NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report
por: Wells, A.E., et al.
Publicado: (2019)

A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report
por: Zhang, Lei, et al.
Publicado: (2021)

A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal
por: Ando, Yuichi, et al.
Publicado: (2022)

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy
por: Lin, Ruihe, et al.
Publicado: (2023)

Larotrectinib for solid tumours
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qa0fd1da7aprv8q91lj834ebe7